PDCD1 and colitis: PD-1-0520 also showed no systemic toxicity in mice—no weight loss or hematological abnormalities were observed (Figure 6B)—a critical advantage over antibodies, which can induce severe immune-related adverse events (e.g., colitis, pneumonitis) due to off-target immune activation.